Not Signed In -
Insulin aspart |
Humalog Aspart; Humulin Aspart; insulin aspart [rDNA origin]; Novolin Aspart; NovoLog |
Clinical Trial: Safety & Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
This study has been completed.
|
Purpose
The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Gestational Diabetes | Drug: Novolog (Insulin Aspart) Drug: Novolin R Drug: Novolin N | Phase III |
MedlinePlus related topics: Diabetes and Pregnancy
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Expected Total Enrollment: 40
Study completion: December 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Female
Accepts Healthy Volunteers
Criteria
Ages Eligible for Study: At least 18 years old. Subjects older than 35 years old will be considered.
Location Information
California
Sansum Medical Research Foundation, Santa Barbara, California, 93105, United States
More Information
Study ID Numbers: ANA-2067
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: July 17, 2003
ClinicalTrials.gov Identifier: NCT00065130
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: July 17, 2003
ClinicalTrials.gov Identifier: NCT00065130
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
